What are the treatment options for systemic amyloidosis?

Treatment for AL Amyloidosis

The current standard first-line treatment for AL amyloidosis is daratumumab combined with cyclophosphamide, bortezomib, and dexamethasone (DaraCyborD), which is the only FDA-approved first-line regimen and achieves rapid, deep hematological responses that translate into improved organ function and survival. 1, 2, 3

Treatment Selection Algorithm

First-Line Therapy Selection

Transplant-eligible patients (~20% of cases):

• Autologous stem cell transplantation (ASCT) remains an option for carefully selected patients with limited organ involvement and good performance status 1
• May be preceded by bortezomib-based induction therapy 1
• However, there is no robust evidence demonstrating superiority over chemotherapy alone 2

Transplant-ineligible patients (majority):

• DaraCyborD (daratumumab + cyclophosphamide + bortezomib + dexamethasone) is the standard of care 1, 2, 3
• Bortezomib-based regimens (CyBorD, BMDex) are central to upfront treatment 1
• Goal: achieve at least very good partial response (VGPR) after 4-6 cycles 2, 3

Treatment Goals and Response Monitoring

Target hematological response:

• Aim for VGPR or better (difference in free light chains [dFLC] <40 mg/L) 1
• Stringent dFLC response (dFLC <5-20 mg/L) predicts better organ responses and prolonged survival 1
• Complete response (CR) with undetectable minimal residual disease (MRD) by next-generation flow cytometry is associated with 90% renal response and 95% cardiac response rates 1

Critical monitoring points:

• Median time to hematological response with daratumumab: 1 week 1
• Monitor cardiac biomarkers (NT-proBNP/BNP, troponin) and free light chains closely 3, 4
• Complete hematological response does not guarantee organ response—MRD assessment provides additional prognostic information 1

Relapsed/Refractory Disease

Second-Line Therapy

Daratumumab or daratumumab-based therapy is the recommended second-line treatment for patients not receiving it upfront 1

• Overall response rate: 63-100%, with most achieving at least VGPR 1
• 2-year overall survival: 74% 1
• Main toxicity: infections due to hypoglobulinemia 1

Third-Line and Beyond

If hematological relapse ≥2 years after last therapy:

• Consider repeating original therapy 1

If not bortezomib-refractory:

• Bortezomib-based regimens (CyBorD, BMDex, or bortezomib-dexamethasone) 1

If bortezomib-refractory:

• Pomalidomide-dexamethasone (pom-dex): Better tolerated than lenalidomide, with 48% overall hematological response rate and median time to response of 1.9 months 1
• Lenalidomide-dexamethasone (len-dex): Use with caution 1

Novel therapies under investigation:

• Venetoclax: Particularly promising for patients with t(11;14) translocation 2
• CAR-T therapy targeting BCMA 2
• Anti-amyloid antibodies to deplete deposited fibrils 5, 3

Critical Management Considerations

Immunomodulatory Drug (IMiD) Toxicity

Lenalidomide concerns:

• Renal deterioration occurs in 66% of patients, reversible in only ~50% 1
• Rising NT-proBNP/BNP indicating cardiac toxicity 1
• Start at low doses (5-15 mg/day), with lower doses for elderly or those with baseline cardiac involvement or elevated creatinine 1
• Monitor daily weights for fluid retention and track cardiac biomarkers closely 1

Pomalidomide is slightly better tolerated with rapid responses (1-3 months) 1

Prognostic Staging

Four-stage system based on:

• NT-proBNP (or BNP)
• Serum troponin T or I
• Difference between involved and uninvolved free light chains 3

5-year survival by stage:

• Stage I: 82%
• Stage II: 62%
• Stage III: 34%
• Stage IV: 20% 3

Common Pitfalls

Delayed diagnosis remains the major obstacle to effective therapy before end-stage organ failure develops 3, 4

• More than 69% of patients have multiple organ involvement at diagnosis 1
• Cardiac involvement is the main driver of prognosis and mortality 1

Treatment must be initiated rapidly before irreversible organ damage occurs 1, 4

ASCT should be reserved for highly selected patients given lack of proven superiority and significant toxicity risk 2

Thalidomide should be avoided due to high toxicity 1